echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > CStone Pharmaceuticals announces that AYVAKIT (avapritinib), a precision targeted drug for gastrointestinal stromal tumors, has been approved in Hong Kong, China

    CStone Pharmaceuticals announces that AYVAKIT (avapritinib), a precision targeted drug for gastrointestinal stromal tumors, has been approved in Hong Kong, China

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    Dr.


    The approval of AYVAKIT ® by the Hong Kong Department of Health is based on the NAVIGATOR study, which is an open-label, dose escalation/dose expansion phase I study to evaluate the safety and efficacy of AYVAKIT ® in patients with unresectable or metastatic GIST


    CStone Pharmaceuticals has reached an exclusive cooperation and licensing agreement with Blueprint Medicines, and has obtained the exclusive development and commercialization authorization for a variety of drugs including AYVAKIT ® in the Greater China region (including Mainland China, Hong Kong, Macau and Taiwan)


    About Gastrointestinal Stromal Tumor ( GIST )

    GIST is a sarcoma that occurs in the gastrointestinal tract.


    About AYVAKIT ® ( avapritinib )

    AYVAKIT ® is a kinase inhibitor, approved by the Hong Kong Department of Health of China under the trade name AYVAKIT ® to treat adult patients with unresectable or metastatic gastrointestinal stromal tumors with PDGFRA D842V mutation


    The US Food and Drug Administration approved it to be marketed under the trade name AYVAKIT ® for the treatment of unresectable or metastatic GIST adult patients with PDGFRA exon 18 mutations (including PDGFRA D842V mutations) and the treatment of advanced systemic mastocytosis Adult patients with advanced SM, including aggressive SM (ASM), SM with hematological tumors (SM-AHN) and mast cell leukemia (MCL)


    Globally, Blueprint Medicines is conducting clinical development for AYVAKIT ® to treat patients with advanced and indolent systemic mastocytosis (SM)


    About CStone Pharmaceuticals

    CStone Pharmaceuticals (Hong Kong Stock Exchange Code: 2616) is a biopharmaceutical company that focuses on research, development and commercialization of innovative tumor immunotherapy and precision treatment drugs to meet the ardent medical needs of cancer patients in China and around the world


    For more information, please visit.


    Forward-looking statement

    The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article


    trademark

    Blueprint Medicines, AYVAKIT, AYVAKYT and related trademarks are owned by Blueprint Medicines Corporation

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.